BioMarinJPM2025

BioMarin Pharmaceutical Inc.Alexander Hardy, President and Chief Executive OfficerJanuary 13, 202543rd AnnualJ.P. Morgan Healthcare Conference2Forward Looking StatementsThis presentation and the associated conference call and webcast contain forward-looking statements about the business prospectsof BioMarin Pharmaceutical Inc. (BioMarin), including, without limitation, statements about: future financial performance, including the expectations ofTotal Revenues, Non-GAAP Operating Margin percentage, Operating Cash Flow and Revenue Compound Annual Growth Rate (CAGR) for future periods and the underlying assumptions; BioMarin’s plans and expectations regarding innovation and growth, including plans regarding business development and clinical-stage external innovation, as well as the anticipated benefits of such plans; ability of BioMarin’s approved products, including VOXZOGO and BioMarin’s enzyme therapies, to drive long-term revenue growth; the clinical development and commercialization